Insurers decline to cover Biogen's new Alzheimer's disease (AD) drug as the fallout continues from the FDA's controversial approval
July 19, 2021 | News Commentary
Biogen's AD drug, Aduhelm, continues to stir controversy, as several private insurers have decided not to cover the high costs of the medication. This includes some affiliates of Blue Cross...
About Lux Research
Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.